Plexium Strengthens Leadership Team With Appointment of Daniel Sipes As Senior Vice President, Head of Technology

Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Daniel Sipes as Senior Vice President, Head of Technology. Mr. Sipes brings over two decades of experience in developing and implementing new technologies for drug discovery to Plexium, with a focus on next-generation high throughput screening and novel assay development.

Continue ReadingPlexium Strengthens Leadership Team With Appointment of Daniel Sipes As Senior Vice President, Head of Technology

Top-Notch Karuna Therapeutics Breaks Out To Record High On Schizophrenia Win

Karuna Therapeutics (KRTX) topped expectations Monday in a study of its schizophrenia treatment, and the biotech stock soared to a record high.On the stock market today, biotech stock Karuna catapulted 71.8% to 241.19. The company tested its drug in patients with schizophrenia for five weeks. At the end of the test, patients who received the drug showed a 9.6-point reduction on a scale of symptoms compared to the placebo recipients. The scale measures 30 items related to psychopathic behavior.

Continue ReadingTop-Notch Karuna Therapeutics Breaks Out To Record High On Schizophrenia Win